Last reviewed · How we verify

NCT07188389: IMEX

Immunometabolism of Exercise

Completed NA Last updated 23 September 2025
What this trial tests

NA trial testing Acute exercise-moderate intensity in Cardiorespiratory Fitness and Acute Exercise in 102 participants. Completed in 3 April 2025.

Timeline
1 March 2024
Primary endpoint
2 April 2025
3 April 2025

Quick facts

Lead sponsorUniversity of Houston
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment102
Start date1 March 2024
Primary completion2 April 2025
Estimated completion3 April 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Houston

Who can join

Adults 20 to 40, any sex, with Cardiorespiratory Fitness and Acute Exercise. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to examine the effects of acute aerobic exercise and cardiorespiratory fitness on cellular metabolism of CD8+ T cells and regulatory T cells (Tregs) found in the peripheral blood of humans. In addition, the study will investigate whether the effects of exercise differ based on exercise intensity, as well as whether the effects of exercise and fitness differ between subpopulations of CD8+ T cells and Tregs. Finally, the study aims to examine whether exercise- and fitness-induced changes in cell metabolism relate to changes in cell function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07188389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing